Exact Sciences CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Exact Sciences Reports 2024 Results, Highlights Cologuard Plus Approval and Strategic Priorities
Exact Sciences delivered over 4.6 million cancer test results in 2024, grew revenue by 10%, and secured FDA approval for Cologuard Plus.
Exact Sciences Corporation achieved significant milestones in 2023, including revenue growth, positive cash flow from operations, and advancements in its product pipeline.